A Randomized, Placebo-Controlled, Double-blind, Dose Escalation Study to Assess Safety,
Efficacy and Pharmacokinetics of GMA301 Injection in Subjects with Pulmonary Arterial
The purpose of this study is to evaluate the effect of macitentan on hemodynamic measures at
Week 24 in pediatric populations.
The purpose of the study is to evaluate the change from baseline to 12 months after study
enrollment in the number of the following non-invasive risk criteria: World Health
Organization Functional Class (WHO/FC), 6-minute walk distance (6MWD), Brain Natriuretic
Peptide (BNP) or N-terminal pro-brain Natriuretic Peptide (NT-proBNP).
Study ROR-PH-302, ADVANCE CAPACITY, is designed to evaluate the effects of ralinepag therapy
on exercise capacity as assessed by change in peak oxygen consumption (VO2) derived from
cardiopulmonary exercise testing (CPET) after 28 weeks of treatment
The purpose of this study is to describe the time to all-cause death and time to death due to
pulmonary arterial hypertension (PAH) or first hospitalization due to PAH in the overall
study population and within each cohort.
The purpose of this study is to assess the safety and efficacy of Rodatristat Ethyl in
pulmonary arterial hypertension (PAH) patients.
The purpose of this study is to evaluate whether the addition of selexipag to standard of
care treatment delays disease progression in children with Pulmonary Arterial Hypertension
(PAH) in comparison to placebo.
The purpose of the study is to assess the effects of selexipag on right ventricular (RV)
function in participants with Pulmonary arterial hypertension (PAH).
The purpose of this study is to assess the long-term safety of selexipag while providing
continued selexipag treatment for participants who were previously enrolled in an
Actelion-sponsored study with selexipag and who derived benefit from selexipag in indications
for which a positive benefit-risk has been established.
The purpose of the study is to assess safety and tolerability of prostacyclin receptor
agonist formulation in treatment period 1 and with different formulation of prostacyclin
receptor agonist in treatment period 2.